Reducing the need for surgical interventions in the management of melanoma

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Piotr Rutkowski, MD, PhD, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, briefly reviews the history and future of treatment approaches for melanoma. The MSLT-II (NCT00297895) and DeCOG-SLT trials (NCT02434107) demonstrated that immediate complete lymph node dissection (CLND) after positive sentinel lymph node (SLN) biopsy had no impact on melanoma-specific survival or recurrence rate and confirmed that CLND is not recommended for patients with SLN metastasis. The SWOG-S1801 (NCT03698019) and NADINA (NCT04949113) trials demonstrated that neoadjuvant therapies led to longer event-free survival and required less extensive surgery for patients with palpable nodes. The PRADO trial (NCT02977052) has shown promising results in reducing the extent of surgery and paves the way for further research. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next